Zelgen’s DLL3 trispecific goes pivotal
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
The month ahead: October’s upcoming events
ESMO and the Triple Meeting approach.
BioNTech tries again with MabVax
BNT329 enters the clinic, as do four other new ADCs.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Alentis doubles down on Claudin1
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
Joyo starts its first pivotal trial
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
